Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RIPRETINIB Cause Blood creatinine increased? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Blood creatinine increased have been filed in association with RIPRETINIB (QINLOCK). This represents 0.3% of all adverse event reports for RIPRETINIB.

11
Reports of Blood creatinine increased with RIPRETINIB
0.3%
of all RIPRETINIB reports
1
Deaths
6
Hospitalizations

How Dangerous Is Blood creatinine increased From RIPRETINIB?

Of the 11 reports, 1 (9.1%) resulted in death, 6 (54.5%) required hospitalization, and 1 (9.1%) were considered life-threatening.

Is Blood creatinine increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RIPRETINIB. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does RIPRETINIB Cause?

Fatigue (582) Alopecia (517) Extra dose administered (357) Death (356) Underdose (345) Nausea (292) Drug ineffective (291) Disease progression (290) Hospitalisation (280) Neoplasm progression (263)

What Other Drugs Cause Blood creatinine increased?

EMTRICITABINE\TENOFOVIR DISOPROXIL (1,966) TENOFOVIR DISOPROXIL (1,460) TACROLIMUS (1,439) METHOTREXATE (1,401) SACUBITRIL\VALSARTAN (1,389) RITUXIMAB (1,265) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (1,112) METFORMIN (986) ECULIZUMAB (967) LENALIDOMIDE (959)

Which RIPRETINIB Alternatives Have Lower Blood creatinine increased Risk?

RIPRETINIB vs RISANKIZUMAB RIPRETINIB vs RISANKIZUMAB-RZAA RIPRETINIB vs RISDIPLAM RIPRETINIB vs RISEDRONATE RIPRETINIB vs RISEDRONIC ACID

Related Pages

RIPRETINIB Full Profile All Blood creatinine increased Reports All Drugs Causing Blood creatinine increased RIPRETINIB Demographics